Methods of treating granulocyte-macrophage progenitor cell-derived blood cell dysfunction
US5942222A · kind A · utility
2Cited by
5References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 1995 |
| Grant date | Aug 24, 1999 |
| Priority date | — |
| Expiry date | Jun 7, 2015 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2400/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the identification of promoters of myelopoietic blood cell production. In particular, an agent has been discovered that enhances myelopoietic colony stimulating factor activity. The agent comprises cytokines that are also capable of binding to heparin, and inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously. Particular agents comprise the inflammatory cytokines MIP-1 and MIP-2. Diagnostic and therapeutic utilities are proposed, and pharmaceutical compositions are likewise set forth.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.